ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 227 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,976 | -7.7% | 92,369 | +2.6% | 0.01% | 0.0% |
| Q2 2023 | $2,141 | +58.9% | 90,000 | +23.8% | 0.01% | +66.7% |
| Q1 2023 | $1,347 | +17.0% | 72,700 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,151 | -99.9% | 72,700 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,160,000 | +13.6% | 72,700 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,021,000 | -42.5% | 72,700 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $1,775,000 | +8.4% | 72,700 | +5.8% | 0.00% | 0.0% |
| Q4 2021 | $1,637,000 | +45.0% | 68,700 | +2.7% | 0.00% | +33.3% |
| Q3 2021 | $1,129,000 | -29.3% | 66,900 | 0.0% | 0.00% | -40.0% |
| Q2 2021 | $1,598,000 | -6.8% | 66,900 | 0.0% | 0.01% | -16.7% |
| Q1 2021 | $1,714,000 | -50.0% | 66,900 | +4.0% | 0.01% | -53.8% |
| Q4 2020 | $3,426,000 | +11.4% | 64,300 | -17.0% | 0.01% | -7.1% |
| Q3 2020 | $3,076,000 | +48.5% | 77,500 | +37.7% | 0.01% | +7.7% |
| Q3 2019 | $2,071,000 | -32.5% | 56,300 | -51.5% | 0.01% | -13.3% |
| Q2 2019 | $3,066,000 | +188.2% | 116,000 | +57.3% | 0.02% | +150.0% |
| Q1 2019 | $1,064,000 | +12.0% | 73,760 | +19.9% | 0.01% | 0.0% |
| Q4 2018 | $950,000 | -10.7% | 61,500 | -16.6% | 0.01% | 0.0% |
| Q3 2018 | $1,064,000 | -5.7% | 73,760 | -1.4% | 0.01% | -14.3% |
| Q2 2018 | $1,128,000 | -19.6% | 74,830 | +23.3% | 0.01% | -30.0% |
| Q1 2018 | $1,403,000 | -35.1% | 60,700 | -11.9% | 0.01% | -41.2% |
| Q4 2017 | $2,163,000 | 0.0% | 68,900 | 0.0% | 0.02% | 0.0% |
| Q3 2017 | $2,163,000 | +9.5% | 68,900 | 0.0% | 0.02% | +6.2% |
| Q2 2017 | $1,976,000 | -15.9% | 68,900 | 0.0% | 0.02% | -27.3% |
| Q1 2017 | $2,349,000 | +9.1% | 68,900 | -8.7% | 0.02% | -4.3% |
| Q4 2016 | $2,153,000 | -34.0% | 75,500 | -24.3% | 0.02% | -36.1% |
| Q3 2016 | $3,263,000 | +3.8% | 99,800 | +2.8% | 0.04% | 0.0% |
| Q2 2016 | $3,144,000 | +136.9% | 97,100 | +90.4% | 0.04% | +125.0% |
| Q1 2016 | $1,327,000 | -27.8% | 51,000 | -0.4% | 0.02% | -23.8% |
| Q4 2015 | $1,837,000 | +10.0% | 51,200 | +1.4% | 0.02% | +5.0% |
| Q3 2015 | $1,670,000 | -18.1% | 50,500 | +3.7% | 0.02% | -16.7% |
| Q2 2015 | $2,040,000 | +33.2% | 48,700 | +3.6% | 0.02% | +26.3% |
| Q1 2015 | $1,532,000 | -9.3% | 47,000 | -11.8% | 0.02% | -9.5% |
| Q4 2014 | $1,689,000 | +17.2% | 53,300 | -8.4% | 0.02% | +5.0% |
| Q3 2014 | $1,441,000 | +12.3% | 58,200 | +2.5% | 0.02% | +5.3% |
| Q2 2014 | $1,283,000 | -4.6% | 56,800 | +2.7% | 0.02% | -9.5% |
| Q1 2014 | $1,345,000 | +4.8% | 55,300 | +9.3% | 0.02% | 0.0% |
| Q4 2013 | $1,284,000 | -5.4% | 50,600 | +2.4% | 0.02% | -12.5% |
| Q3 2013 | $1,357,000 | +58.0% | 49,400 | +6.0% | 0.02% | +41.2% |
| Q2 2013 | $859,000 | – | 46,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |